<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03982862</url>
  </required_header>
  <id_info>
    <org_study_id>KMUHIRB-F(II)-20180062</org_study_id>
    <nct_id>NCT03982862</nct_id>
  </id_info>
  <brief_title>Botulinum Toxins Intralesional Injection for Scar Pain</brief_title>
  <official_title>Intralesional Injection of Steroids and/or Botulinum Toxin Type A in Hypertrophic Scars and Keloids for Pain Improvement</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kaohsiung Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kaohsiung Medical University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Botulinum toxins has been approved by the FDA to treat chronic migraine. Botox had been shown
      to inhibiting the release of inflammatory mediators and peripheral neurotransmitters from
      sensory nerve to treat neuropathic pain. In the clinical practice, botox indeed effect in
      scar pain. However, investigators need well controlled study to prove this finding and assess
      the improvement of scar appearance.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      After surgery or trauma, scar tissues would form during the healing process. However,
      hypertrophic scars and keloids might happen to some patients, both of which are often
      pruritic and erythematous. Besides, the markedly elevated tumor-like appearance usually
      brings much concern to patients. Moreover, significant pain or discomfort could happen to
      keloids. Various treatment strategies were mentioned but without a solid solution to all of
      the scars. Investigators hope to evaluate the differences of scar volume, appearance and
      symptoms (itching and pain) in participants receiving simultaneous intralesional injection of
      Botulinum toxin type A and/or steroids. Besides, side effects would also be recorded.
      Investigators hope to establish a more effective intralesional injection therapy for
      participatns suffering from hypertrophic scars and keloids.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 30, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2019</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Scar pain relief</measure>
    <time_frame>Change from baseline scar pain during 16 weeks after drug injection</time_frame>
    <description>assessed by score 0,1,2 (0: no pain, 1: sometimes feel pain, 2: need medication)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>scar appearance</measure>
    <time_frame>Change from baseline scar appearance during 16 weeks after drug injection</time_frame>
    <description>assessed by vancouver scar scale(vascularity, pigmentation, pliability, height)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>itch</measure>
    <time_frame>Change from baseline itch sensation during 16 weeks after drug injection</time_frame>
    <description>assessed by score 0,1,2 (0: no itch, 1: sometimes feel itch, 2: need medication)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">20</enrollment>
  <condition>Scar Keloid</condition>
  <condition>Hypertrophic Scar</condition>
  <arm_group>
    <arm_group_label>control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>0.9% Normal saline 0.1 ml +Triamcinolone 4mg diluted to 0.1 ml + 0.1ml 2% Xylocaine per 1cm2 scar volume</description>
  </arm_group>
  <arm_group>
    <arm_group_label>botox group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4U Botox® diluted to 0.1 ml + Triamcinolone 4mg diluted to 0.1 ml + 0.1ml 2% Xylocaine per 1 cm2 scar volume</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Triamcinolone</intervention_name>
    <description>Triamcinolone 4mg diluted to 0.1 ml</description>
    <arm_group_label>botox group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>steroid</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lidocaine</intervention_name>
    <description>0.1ml 2% Xylocaine</description>
    <arm_group_label>botox group</arm_group_label>
    <arm_group_label>control group</arm_group_label>
    <other_name>Xylocaine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Botulinum toxin A</intervention_name>
    <description>4U Botox® diluted to 0.1 ml</description>
    <arm_group_label>botox group</arm_group_label>
    <other_name>botox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients have visible hypertrophic scars or keloids over three months after trauma or
             surgery.

          2. Patients have symptoms of pain, itching or erythema.

        Exclusion Criteria:

          1. Patients had either Botulinum toxin type A or Triamcinolone intralesional before in
             the same scar

          2. The scar size is larger than 10 cm2

          3. Immunocompromised status

          4. Systemic infection status

          5. Allergic to Botulinum toxin type A or steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shu Hung Huang, MD, PHD</last_name>
    <role>Study Director</role>
    <affiliation>Kaohsiung Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shu hung Huang, MD, PHD</last_name>
    <phone>886-3121101</phone>
    <phone_ext>6866</phone_ext>
    <email>huangsh63@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kaohsiung Medical University Hospital</name>
      <address>
        <city>Kaohsiung</city>
        <country>Taiwan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shu Hung Huang, MD, PHD</last_name>
      <phone>886-3121101</phone>
      <phone_ext>6866</phone_ext>
      <email>huangsh63@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Taiwan</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>June 9, 2019</study_first_submitted>
  <study_first_submitted_qc>June 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 12, 2019</study_first_posted>
  <last_update_submitted>June 13, 2019</last_update_submitted>
  <last_update_submitted_qc>June 13, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 17, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kaohsiung Medical University</investigator_affiliation>
    <investigator_full_name>Sheng-Hua Wu</investigator_full_name>
    <investigator_title>Attending Physician, anesthesiology</investigator_title>
  </responsible_party>
  <keyword>Botulinum toxin type A</keyword>
  <keyword>Triamcinolone</keyword>
  <keyword>scar pain</keyword>
  <keyword>scar itch</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keloid</mesh_term>
    <mesh_term>Cicatrix</mesh_term>
    <mesh_term>Hypertrophy</mesh_term>
    <mesh_term>Cicatrix, Hypertrophic</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Triamcinolone</mesh_term>
    <mesh_term>Lidocaine</mesh_term>
    <mesh_term>Botulinum Toxins</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>abobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

